Protective Activity of Novel Hydrophilic Synthetic Neurosteroids on Organophosphate Status Epilepticus-induced Chronic Epileptic Seizures, Non-Convulsive Discharges, High-Frequency Oscillations, and Electrographic Ictal Biomarkers.

J Pharmacol Exp Ther

Department of Neuroscience and Experimental Therapeutics (S.R., T.S., D.S.R.) and Institute of Pharmacology and Neurotherapeutics (D.S.R.), School of Medicine, Texas A&M University Health Science Center, Bryan, Texas

Published: January 2024

Nerve agents and organophosphates (OP) are neurotoxic chemicals that induce acute seizures, status epilepticus (SE), and mortality. Long-term neurologic and neurodegenerative effects manifest months to years after OP exposure. Current benzodiazepine anticonvulsants are ineffective in preventing such long-term neurobehavioral and neuropathological changes. New and effective anticonvulsants are needed for OP intoxication, especially for mitigating the long-term sequelae after acute exposure. We developed neurosteroids as novel anticonvulsants and neuroprotectants in OP exposure models. In this study, we evaluated the long-term efficacy of novel synthetic neurosteroids in preventing the development of chronic epilepsy and hyperexcitable ictal events in a rat OP model of SE. Rats were exposed to the OP nerve agent surrogate diisopropylfluorophosphate (DFP), and the experimental groups were treated with the synthetic neurosteroid valaxanolone (VX) or lysaxanolone (LX) 40 minutes post-exposure in conjunction with midazolam. Video-electroencephalography was monitored for two months to assess spontaneous recurrent seizures (SRS), epileptiform discharges, interictal spikes, and high-frequency oscillations (HFOs). Within 60 days of DFP exposure, rats developed chronic epilepsy characterized by frequent SRS, epileptiform discharges, and HFOs. LX treatment was associated with a dose-dependent reduction of epilepsy occurrence and overall seizure burden with a significant decrease in SRS and epileptiform discharges. It also significantly reduced the occurrence of epileptic biomarkers of HFOs and interictal spikes, indicating potential disease-modifying activity. Similarly, the neurosteroid analog VX also significantly attenuated SRS, discharges, HFOs, and ictal events. These results demonstrate the long-term protective effects of synthetic neurosteroids in the OP-exposed post-SE model, indicating their disease-modifying potential to prevent epilepsy and ictal abnormalities. SIGNIFICANCE STATEMENT: The effects of nerve agents and organophosphate (OP) exposure are persistent, and survivors suffer from a number of devastating, chronic neurological dysfunctions. Currently, there is no specific therapy for preventing this disastrous impact of OP exposure. We propose synthetic neurosteroids that activate tonic inhibition provide viable options for preventing the long-term neurological effects of OP intoxication. The results from this study reveal the disease-modifying potential of two novel synthetic neurosteroids in preventing epileptogenesis and chronic epileptic seizures after OP-induced SE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10801763PMC
http://dx.doi.org/10.1124/jpet.123.001817DOI Listing

Publication Analysis

Top Keywords

synthetic neurosteroids
20
srs epileptiform
12
epileptiform discharges
12
chronic epileptic
8
epileptic seizures
8
high-frequency oscillations
8
nerve agents
8
preventing long-term
8
novel synthetic
8
neurosteroids preventing
8

Similar Publications

Background: Brexanolone (Zulresso) and zuranolone (Zurzuvae) are two synthetic neuroactive steroids that were approved by the U.S. Food and Drug Administration in March 2019 (as an intravenous treatment) and August 2023 (as an oral treatment) respectively, for the treatment of postpartum depression.

View Article and Find Full Text PDF

Transient receptor potential channel subfamily M member 3 (TRPM3) is a Ca-permeable cation channel activated by the neurosteroid pregnenolone sulfate (PregS) or heat, serving as a nociceptor in the peripheral sensory system. Recent discoveries of autosomal dominant neurodevelopmental disorders caused by gain-of-function mutations in TRPM3 highlight its role in the central nervous system. Notably, the TRPM3 inhibitor primidone, an anticonvulsant, has proven effective in treating patients with TRPM3-linked neurological disorders and in mouse models of thermal nociception.

View Article and Find Full Text PDF

Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies.

Rev Bras Ginecol Obstet

December 2024

Beaumont Hospital Department of Gynaecology Dublin Ireland Department of Gynaecology, Beaumont Hospital, Beaumont Rd, Dublin, Ireland.

Article Synopsis
  • The study aimed to assess the effectiveness and safety of zuranolone, an oral medication for postpartum depression (PPD), by comparing it to a placebo in randomized trials.
  • A systematic search identified 11 relevant papers, leading to a detailed analysis of 2 studies involving 346 women, where zuranolone showed significant improvements in depression symptoms and reduced need for other antidepressants.
  • While zuranolone appeared to be safe and effective for treating PPD, concerns about increased sedation risk necessitate further investigation.
View Article and Find Full Text PDF

LPM682000012, a Synthetic Neuroactive Steroid That Ameliorates Epileptic Seizures by Downregulating the /NF-κB Signaling Pathway.

Molecules

November 2024

Key Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.

Epilepsy is characterized by abnormal neuronal firing in the brain. Several therapeutic strategies exist for epilepsy; however, several patients remain poorly treated. Therefore, the development of effective treatments remains a high priority in the field.

View Article and Find Full Text PDF

Gamma-aminobutyric acid type A receptor (GABAR) modulators are crucial in treating neurological and psychiatric disorders, including epilepsy, anxiety, insomnia, and depression. This review examines the synthetic approaches and clinical applications of representative small-molecule GABAR modulators. Benzodiazepines, such as Diazepam, are well-known positive allosteric modulators (PAMs) that enhance GABAR function, providing therapeutic effects but also associated with side effects like sedation and dependence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!